Cantor Fitzgerald Forecasts uniQure FY2025 Earnings

uniQure (NASDAQ:QURE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for uniQure in a research note issued on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska expects that the biotechnology company will post earnings per share of ($2.76) for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.75) per share.

Several other equities research analysts have also recently commented on QURE. StockNews.com raised shares of uniQure to a "sell" rating in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of uniQure in a research report on Monday, April 21st. Chardan Capital reiterated a "buy" rating and issued a $38.00 price target on shares of uniQure in a research note on Monday, May 12th. Guggenheim reissued a "buy" rating and set a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Finally, Wells Fargo & Company cut their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.

uniQure Stock Performance

NASDAQ:QURE opened at $15.31 on Wednesday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The firm's fifty day simple moving average is $12.37 and its 200 day simple moving average is $12.45. The stock has a market cap of $838.62 million, a P/E ratio of -3.09 and a beta of 0.10. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million.

Insider Activity

In other news, CEO Matthew C. Kapusta sold 26,727 shares of uniQure stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now owns 571,188 shares of the company's stock, valued at $6,111,711.60. The trade was a 4.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christian Klemt sold 14,341 shares of the business's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. This trade represents a 8.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 90,830 shares of company stock worth $961,401. Company insiders own 4.74% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its position in shares of uniQure by 453.2% during the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after buying an additional 502,684 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in uniQure during the fourth quarter worth $320,000. Palumbo Wealth Management LLC purchased a new position in uniQure during the fourth quarter valued at $437,000. Raymond James Financial Inc. acquired a new stake in shares of uniQure in the fourth quarter valued at about $1,951,000. Finally, Geode Capital Management LLC grew its position in shares of uniQure by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock valued at $9,198,000 after purchasing an additional 11,951 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.